Vion Pharmaceuticals Inc Watch

from 10-Q 1 page Amendment No. 5 Dated as of June 24, 2009, to Employment Agreement, Dated as of November 3, 2003, by and Between Vion Pharmaceuticals, Inc. and Alan Kessman

from 10-Q 1 page Form of Non-Equity Incentive Compensation Plan Agreement

from 10-K 2 pages Amendment #2 to the Clinical Trial Agreement Between Vion Pharmaceuticals, Inc. and the Division of Cancer Treatment and Diagnosis, Nci Dated January 8, 2008 Signatures Appear on the Next Page 92

from 10-K 2 pages Amendment #1 to the Clinical Trial Agreement Between Vion Pharmaceuticals, Inc. and the Division of Cancer Treatment and Diagnosis, Nci Dated March 2, 2006

from POS AM 2 pages Employment Offer Letter to Tanya Lewis

from POS AM 2 pages Employment Offer Letter to Tanya Lewis

from 10-Q 2 pages Form of Retention Plan Agreement

from 8-K 5 pages Third Amendment to Lease

from 8-K 4 pages Employment Agreement

from 10-K 2 pages *** Certain Portions of This Exhibit Have Been Omitted Pursuant to a Request for Confidential Treatment Under Rule 24b-2 of the Securities Exchange Act of 1934. the Omitted Materials Have Been Filed Separately With the Securities and Exchange Commission *** First Amendment to a License Agreement Between Johnson & Johnson Consumer Companies, Inc. and Vion Pharmaceuticals, Inc. Dated December 31, 2007

from 10-K 3 pages Employment Offer Letter to William F. Hahne Dated December 23, 2007

from 8-K 3 pages Amendment No. 3, Dated as of February 13, 2008, to Employment Agreement, Dated as of November 3, 2003, by and Between Vion Pharmaceuticals, Inc., a Delaware Corporation (The “Company”), and Alan Kessman (The “Executive”), as Amended by Amendment No. 1 Thereto, Dated September 13, 2005, and Amendment No. 2 Thereto, Dated January 3, 2006 (Collectively, the “2003 Agreement”). Whereas, the Executive Has Been Acting as the Chief Executive Officer of the Company Pursuant to the 2003 Agreement; and Whereas, the 2003 Agreement Provides That the Executive Is Eligible for an Annual Bonus Based on the Achievement of Specified Company Goals With a Maximum Bonus of 50% of Base Salary During the Fiscal Year With Respect to Which Such Bonus Is Awarded; and Whereas, the Board of Directors of the Company (The “Board”) Has Determined That the Executive Is Entitled to a Bonus of $98,568.00 for the 2007 Fiscal Year (The “2007 Bonus”) Based on the Achievement of Specified Company Goals for the 2007 Fiscal Year; and Whereas, the Executive Is Willing to Defer Payment of the 2007 Bonus and the Board Is Desirous of Deferring Payment of the 2007 Bonus; and Whereas, in Order to Effectuate the Foregoing, the Company and the Executive Wish to Amend the 2003 Agreement. Now Therefore, in Consideration of Premises and the Respective Covenants and Agreements of the Parties Herein Contained, and Intending to Be Legally Bound Hereby, the Parties Hereto Agree as Follows: 1. Section 5(b) of the 2003 Agreement Is Hereby Amended and Restated in Its Entirety to Read as Follows: “(B)

from 10-Q ~10 pages Vion Pharmaceuticals, Inc. 2005 Stock Incentive Plan, as Amended and Restated

from 8-K ~10 pages Second Amendment to Lease

from S-3/A 31 pages $60,000,000 Vion Pharmaceuticals, Inc. 7.75% Convertible Senior Notes Due 2012 Warrants to Purchase 7,800,000 Shares of Common Stock Purchase Agreement

from 10-Q ~1 page Employment Offer Letter to James Tanguay Dated March 9, 2007

from 10-Q ~50 pages Amendment to Master Supply Agreement

from 8-K/A 73 pages Confidential Attachments

from 10-Q ~5 pages Employment Offer Letter to Aileen Ryan Dated June 19, 2006

from 10-Q ~1 page Employment Offer Letter to Meghan Fitzgerald Dated December 13, 2005